Secondary Peritonitis, Abscess, Intra-Abdominal
Conditions
Keywords
Moxifloxacin,, cIAI, non-interventional
Brief summary
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.
Interventions
The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin infusion with/without sequential tablet treatment can be included into the study. The local Moxifloxacin product information must be considered.
Exclusion criteria
* Contraindications stated in the local Moxifloxacin product information. Warnings and precautions, stated in the local Moxifloxacin product information must be considered as potential
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Types of cIAI infections | Day 1 |
Secondary
| Measure | Time frame |
|---|---|
| Cure rate | 5-14 days |
| Clinical signs and symptoms | 5-14 days |
| Duration until improvement and cure | 5-14 days |
| Adverse event collection | 5-14 days |
Countries
China
Outcome results
None listed